SLC5A1 and heart failure: Recent clinical trials, SOLOIST (effect of sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure) and SCORED (effect of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes and moderate renal impairment who are at cardiovascular risk), also raised the possible advantage of additional SGLT1 inhibition for cardiovascular outcomes [43, 44].